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BACI<GROUND: Multiple drug immunosuppression has allowed the near elimination of rejection, but without com-
mensurate improvements in longterm graft survival and at the cost of quality of life. We have 
suggested that transplantation outcomes can be improved by modifYing the timing and dosage of 
immunosuppression to facilitate natural mechanisms of alloengraftment and acquired tolerance. 
STUDY DESIGN: Two therapeutic principles were applied for kidney transplantation: pretransplant recipient 
conditioning with antilymphoid antibody preparations (Thymoglobulin [SangstatJ or Cam-
path [ILEX Pharmaceuticals]), and minimal posttransplant immunosuppression with tacroli-
mus monotherapy including "spaced weaning" of maintenance doses when possible. The results 
in Thymoglobulin- (n = 101) and Campath-pretreated renal transplantation recipients (n = 
90) were compared with those in 152 conventionally immunosuppressed recipients in the 
immediately preceding era. 
RESULTS: Spaced weaning was attempted in more than 90% of the kidney transplant recipients after pretreat-
ment with both lymphoid-depleting agents, and is currently in effect in two-thirds of the survivors. 
Although there was a much higher rate of acute rejection in the Thymoglobulin-pretreated recipients 
than in either the Campath-pretreated or historic control recipients, patient and graft survival in 
both lymphoid depletion groups is at least equivalent to that of historic control patients. In the 
Thymoglobulin-conditioned patients for whom followups are now 24 to 40 months, chronic allo-
graft nephropathy (CAN) progressed at the same rate as in historic control patients. Selected patients 
on weaning developed donor-specific nonreactivity. 
CONCLUSIONS: After lymphoid depletion, kidney transplantation can be readily accomplished under minimal 
immunosuppression with less dependence on late maintenance immunosuppression and a 
better quality of life. Campath was the more effective agent for pretreatment. Guidelines for 
spaced weaning need additional refinement. (] Am CoIl Surg 2005;200:505-515. © 2005 by V-
the American College of Surgeons) 
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Kidney transplantation became a practical clinical service 
after it was shown that rejections developing under azathio-
prine were highly reversible with prednisone, and that the 
reversals orren were succeeded by the emergence of variable 
donor-specific nonreactivity (ie, tolerance). 1 In 1966, anti-
lymphoid globulin (ALG) was added to azathioprine and 
prednisone as a steroid-sparing adjunct.2 A short course of 
antilymphoid globulin was begun preoperatively and con-
tinued for several posttransplant days or weeks.2•3 The pre-
transplant portion of the course was subsequently deem-
phasized and omitted because of uncertainty about its value 
and because the time constraints of cadaveric transplanta-
tion made the pretreatment impractical. Instead, antilym-
phoid globulin usually was started on the day of, or day 
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after, transplantation (induction therapy), and in addition, 
prednisone or other agents were increasingly instituted at 
this time in multiple drug regimens designed to eliminate 
the threat of acute rejection.4 
After elucidation of the mechanisms of alloengraft-
5 G • th tho ment,' It was apparent at 1S treatment policy could 
subvert the seminal mechanism of clonal exhauscion-
deletion? Consequendy, we suggested modifications of 
immunosuppression in accordance with two principles. 
The first was lymphoid depletion before rather than after 
transplantation to reduce the anticipated donor-specific re-
sponse into a more easily deletable range. The second was 
avoidance of so much posttransplant immunosuppression 
that the immune activation-dependent mechanism of 
clonal exhaustion-deletion would be interdicted. Pretrans-
plant conditioning was done with a single infusion of rabbit 
antithymocyte globulin (rATG, Thymoglobulin [Gen-
zymel]),B.9 or alternatively, of alemtuzumab (Campath IH 
[ILEX Pharmaceuticals]).1O-14 Minimalistic posttransplant 
immunosuppression was begun with relatively low doses of 
tacrolimus monotherapy with the intention of dose wean-
ing after the first few months of highest immunologic risk. 
Our initial experienceJ5•J6 and that reported here suggest 
that this approach to management can be carried out effi-
ciendy and safely. 
METHODS 
Institutional review process 
Modifications in the timing and dosage of conventional 
immunosuppression were undertaken in July 2001. The 
primary purpose was to improve the quality-of-life out-
comes and patient and graft survival across the full spec-
trum of all kinds of adult kidney recipients in.our clinical 
practice. The modifications were submitted in this context 
to the University of Pittsburgh Institutional Review Board 
(IRB), which judged the changes to be within the bound-
aries of historically based standard treatment. The treat-
ment protocols were reviewed by the Presbyterian Univer-
sity Hospital Committee on Innovative Practices and the 
Pharmacy and Therapeutic Practices Committee, with ap-
proval by both. All patients provided informed consent. In 
addition, separate informed consent was obtained with 
IRB approval for studies of immune variables not routinely 
assayed in our conventional practice. Safety and efficacy 
monitoring were assured by formal weekly reviews of all 
patients. 
Patient selection 
No adult kidney recipients were denied access to the re-
forms in management because of high risk factors. Recipi-
ents who received previous, simultaneous, or subsequent 
nonkidney solid organ allografts or bone marrow were re-
moved from this analysis, as were kidney-only transplanta-
tions performed in the period of time when Thymoglobu-
lin and Campath pretreatment were both used. The three 
study populations were compiled during the eras of March 
2000 to July 200 1 (historic controls, no pretreatment: n = 
152); July 2001 to October 2002 (Thymoglobulin pre-
treatment: n = 101); and March 2003 to September 2003 
(Campath pretreatment: n = 90) (Table 1). 
Differences in donor characteristics reflected nation-
wide efforts to expand the donor pool by using older 
deceased donors and more living donors. The large com-
plement of nonrelated live donors (mostly spousal) is 
noteworthy. The mean histocompatibility match was 
worst and the mean ischemic time best in the Campath 
pretreatment series. Differences in recipient demo-
graphic factors were not statistically significant. 
Immunosuppression 
Historic controls 
Patients treated between March 2000 and June 2001 
received multidrug immunosuppression that included 
tacrolimus, a 5-day intravenous and oral prednisone 
taper (200 ~ 40 mg in 40 mg decrements) followed by 
oral prednisone (20 mg/d) and often a third agent (usu-
ally mycophenolate mofetil or sirolimus). The multiagent 
immunosuppression (particularly the steroid compo-
nent) was weaned slowly throughout the first 6 to 12 
posttransplant months. 
Lymphoid depletion 
Lymphoid depletion between July 2001 and October 
2002 was done with an infusion of 5 mg/kg rabbit anti-
thymocyte globulin (rATG, Thymoglobulin). The Thy-
moglobulin was administered over several hours before 
allograft reperfusion. The antibody infusion was accom-
panied by 1 or 2 g methylprednisolone to prevent cyto-
kine release consequences. The same steroid doses were 
used when alemtuzumab (anti-CD 52 mAb, Campath 
I-H) infusion of 30 mg was substituted for Thymo-
globulin as the conditioning agent. 
Mlnimallstfc immunosuppression 
The lymphoid depleted patients were started on twice 
daily tacrolimus (Prograf) on postoperative day 1, with a 
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Table 1.. Population Characteristics 
Historic Thymoglobulin Campath 
Characteristic controls pretreatment pretreatment 
n 152 101 90 
Accrual dates 3/00 to 7101 7/01 to 10/02 3103 to 9/03 
Followup, (mo) 39 to 54 23 to 39 12 to 18 
Recipient age, (y) 50.6:±: 14.9 51.1 :±: 14.5 50.8 :±: 16.6 
Recipient gender (M/F), % 61/39 65/35 63/37 
African-American recipients, % 14 14 18 
Primary Tx/Re-Tx, % 78/22 85/15 87/13 
Recipient PRA > 20%, % 26 18 19 
Donor age, (y) 35.5 :±: 18.0 39.4 :±: 15.4 41.7 :t 16.0 
Donor gender (M/F), % 57/43 40/60 47/53 
·African-American donors, % 10 
.9 8 
Livingl cadaveric donors, % 20/80 46/54 39/61 
Sibling-sibling 12 14 6 
Parent-offspring 1 6 4 
Offspring-parent 3 7 5 
Other related 3 5 4 
Nonrelated (inc!. spouse) 11 14 16 
Cadaveric ischemia time, (h) 27.7:±: 8.69 26.4 :!: 6.37 20.8:t 7.64 
ABDR mismatch 3.21 :±: 1.61 3.12:!: 1.72 3.64:t 1.57 
Significant variations of the lymphoid depletionl minimum immunosuppression populations as compared with the historic controls are highlighted in bold with 
p ranging from 0.04 to less than 0.001. All significant differences in the populations are attributable to the cadaveric donor subgroup, because jive donor 
characteristics were statistically similar. 
ABDR,; PRA, panel reactive antibodies; Tx, transplant; Re-Tx 
target 12-hour trough level of 10 ng/mL. In a few cases, 
sirolimus (or cyclosporine) was substituted for tacroli-
mus because of nephro- or neurotoxicity. Renal function 
was monitored primarily with serum creatinine determi-
nations. Suspected rejection was confirmed by biopsy 
and treated with one or more boluses of methylpred-
nisolone, muronmonab-CD3 (OKT3), or alemtu-
zumab. Oral steroids or other secondary agents such as 
sirolimus were added only as necessary. 
Spaced weaning 
At some time after 3 to 4 months in lymphoid depleted 
patients who had been stable on tacrolimus monotherapy, 
the twice daily doses were consolidated to a single daily 
dose. For example, someone on 2 mg twice a day would be 
converted to a single 4-mg dose. One and a half or more 
months later, weaning to every-other-day dosing was begun 
(ie, 4 mg every other day). Subsequent weaning to three 
times weekly, twice weekly, and once weekly tacrolimus was 
instituted on an individualized basis. 
Cellular immunologic monitoring 
Peripheral blood mononuclear cells were obtained from 
recipients who had been followed up for 1 year or more. 
The cells were separated by a standard gradient centrif-
ugation methodl7 and used fresh for in vitro functional 
assays. 
Leukocyte surface markers 
Three- or four-color flow cytometry with appropriate 
flurochrome conjugated mAb combinations, and 
isotype-matched nonspecific mAbs (negative controls) 
were used to determine lymphocyte subsets. Data acqui-
sition and analysis was performed on a Coulter EPICS 
XL flow"cytometer (Beckman Coulter Corp). In con-. 
ventionally gated cells for lymphocytes, 50,000 CD45 + 
events were typically collected per sample and analyzed 
with EXP032 software (Applied Cytometry System). 17.l8 
Mixed lymphocyte reaction 
Conventional unidirectional mixed lymphocyte reac-
tion (MLR) cultures were set up for 6 days using 1 X 105 
irradiated stimulator cells (2000R). The degree of [3H] 
thymidine incorporation was assessed during the final 
20 hours of incubation. 
Cell-mediated Iymphocytoxicify 
The cytolytic activity of recipient lymphocytes toward 
donor and third party targets was assessed in cell-
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Agure 1. Patient and graft survival in historic control (00), Thymoglobulin-pretreated (X), and Campath-
pretreated (black squares) kidney recipients. 
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Table 2. Mean Creatinine (mg/dL) at Successive Posttransplant Times of Allografts that Still Function 
n 1. wk 1 mo 3 mo 6 mo 1y 2y 3y Current 
Historic concrols (n - 113) 
Mean 4.45 2.03 1.75 1.68 1.56 1.48 1.53 1.64 
SD 4.13 1.47 0.89 0.59 0.57 0.56 0.79 1.02 
Thymoglobulin (n = 83) 
Mean 3.90 2.24 1.84 1.60 1.58 1.89' 2.08' 
SD 4.32 1.14 1.08 0.62 0.55 0.95 1.23 
Campath (n = 84) 
Mean 1.95 1.74 1.54 1.47 1.59 1.69 
SD 1.60 0.71 0.58 0.54 0.75 0.83 
P Value <0.001 0.025 0.073 0.051 0.957 <0.001 
'Removal of5% (n = 4) of the outlying results for the Thymoglobulin group results in 2-y and current creatinines of 1.74 :!: 0.07 and 1.86 :!: 0.86, respectively. 
mediated lymphocytotoxicity. In these assays, effector 
lymphocytes were incubated with Cr-labeled donor 
phytohemagglutinin-induced target cells at various E:T 
ratios, ranging from 10: 1 to 30: 1. 
Limiting dilution assay 
Cytolytic T lymphocyte precursor frequency was ana-
lyzed as previously described by Kaminski and col-
leagues19 using recipient cells as responders and donor 
cells as stimulators, with the addition on days 4 and 6 of 
recombinant interleukin-2 to fresh medium to give a 
final concentration of 10 U/mL. On day 10, a cytotoxic 
assay was carried out for each culture using 51Cr-Iabeled 
phytohemagglutinin-induced blast cells from the origi-
nal stimulator as the targets. Supernatants harvested 
from each well were measured for 51Cr along with 
appropriate positive and negative controls; cytolytic T 
lymphocyte precursor frequency was considered as min-
imum or background with frequencies of less than 1 in 
300,000.20•21 
Antibody monitoring 
Lymphocytotoxic crossmatches were negative in all 
cases. The pre- and posttransplant sera of 92 recipients 
were screened by ELISA for the presence of IgG anti-
HLA class I and class II alloantibodies according to the 
manufacturer's instructions (One Lambda Inc). The re-
sulting optical densities were analyzed by LATTM soft-
ware for Windows (One Lambda Inc).22.23 
Pathologic stUdies 
Posttransplant biopsies were not taken on protocol but 
rather because of clinical evidence (or suspicion) of re-
jection. But a few biopsies in the historic control patients 
were obtained in pursuit of unrelated research projects, 
and some of the lymphoid depleted patients had baseline 
biopsies before beginning spaced weaning. 
Tissues were handled according to hospital proce-
dures. 15 Biopsy findings were categorized by the stan-
dardized Banff system24 and CAN was scored with a 
scale of 0 to 3 for each of four kinds of abnormality: 
100% 
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Figure 2. Incidence and time to first acute rejection in historic 
control (00), Thymoglobulin-pretreated (X), and Cam path-pretreated 
(black squares) recipients. 
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Figure 3, Variable preweaning courses and weaning outcomes in Thymoglobulin-pretreated kidney recipients. Solid shade = daily 
tacrolimus (Tac) dosing, Spaced weaning represented by spikes that indicate frequency and dose. (A) Uncomplicated weaning from 
daily to once weekly doses of tacrolimus between 4 and 10 posttransplant mo in a cadaver kidney recipient who has been rejection 
free for more than 3 y. (6) Spaced weaning begun after 7 mo after a difficult rejection at 21h mo. Tacrolimus doses have been three 
times per week for the past year in this recipient of a kidney from a live unrelated donor. (e) Reweaning in a patient who developed 
a mild rejection after 9 mo on one dose of tacrolimus per week. The eventual (and current) dose is three times per week. (0) 
Irreversible rejection of a cadaver kidney 4 wk after an attempt to reduce tacrolimus doses to every other day. The patient's original 
disease was lupus nephritis. 
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glomerulopathy (cg), interstitial fibrosis (ci), tubular 
atrophy (ct), and chronic vasculopathy (cv). 
Data management and statistical analysis 
An honest brokering system approved by the University 
of Pittsburgh IRB was used for data management. Data 
were extracted, related, reviewed, augmented (where re-
quired) for accuracy and completeness, and deidentified 
for statistical analysis. Differences in means and stan-
dard deviations calculated from participant characteris-
tics by treatment group were evaluated for the statistical 
significance using t-tests and ANOVAs for continuous 
comparisons and chi-square tests for categorical com-
parisons. Kaplan-Meier survival curves were generated 
and evaluated for significance using a log-rank test. 
Kaplan-Meier comparisons were adjusted for significant 
population differences to ascertain their effect. A p value 
<0.05 two sided was considered significant. 
RESULTS 
Survival and graft function 
Survival 
Survival of live donor grafts (Fig. 1) was better in both 
the Thymoglobulin- and Campath-pretreated patients 
than in the live donor historic controls (p < 0.037). 
Otherwise, patient and graft survival were not signifi-
cantly different in either of the lymphoid depletion pop-
ulations versus the historic controls overall (p = 0.12 to 
0.59) or in the subgroups of the respective cadaveric or 
liver donor recipients (p = 0.25 to 0.61); These findings 
did not change when survival was adjusted for popula-
tion differences. 
Graft function 
Cam path-pretreated patients had the best early mean 
serum creatinine, but there was no difference in the 
three populations at 1 year (see Table 2). Mean serum 
creatinine at 2 years and currently in Thymoglobulin-
pretreated patients was higher than in historic con-
trols, mostly because of four outliers (see footnote to 
Table 2). 
Rate of acute rejection 
The three groups showed a markedly different inci-
dence and time to acute rejection (Fig. 2). In the 
Thymoglobulin-pretreated patients, the onset of rejec-
tion was earlier (p < 0.001) and the incidence was higher 
than in either the Campath or historic control recipients. 
Transplantation with Reduced Immunosuppression 5U 
The incidence of rejection during the first 6 months after 
Campath pretreatment was 1 %. Rejections that occurred 
after 6 months were frequently associated in both the 
Thymoglobulin- and Campath-pretreatment groups with 
attempts to space wean (see below). 
Weaning 
After Thymoglobulin pretreatment 
Spaced weaning was attempted in 91 (90.1 %) of the 101 
recipients after a mean of 5.9 :±: 1.4 months. Clinical 
courses were highly variable before and after weaning. 
The weaning process was uncomplicated in the majority 
of cases in which it was attempted (Fig. 3A and B). But 
in 45% of the patients in whom spaced weaning was 
started, daily therapy was resumed because of acute re-
jection. If the rejection promptly responded to 1 or 2 
boluses of prednisone, less aggressive spaced weaning 
subsequently was resumed (Fig. 3C). 
Weaning either could not be successfully done or was 
never attempted in about one-third of the recipients. In 
some of these patients and in others in whom spaced 
weaned was never tried, grafts were lost to nonreversible 
rejection. In the patient depicted in Figure 3D, the orig-
inal renal disease was lupus nephritis. 
With followups of 24 to 39 months, 68% of the 83 
patients with currently surviving grafts are on spaced 
doses of maintenance immunosuppression. Another 
25% are on daily monotherapy. Only 7% are receiving 
more than one immunosuppressant (Table 3). 
After Campath pretreatment 
Spaced weaning was attempted in 83 (91.2%) of the 90 
. patients after a mean of 6.3 :±: 1.2 months. The decision 
to go forward with weaning was more straightforward 
than it was in the Thymoglobulin-conditioned patients 
because of the nearly complete absence of preweaning 
rejection. In addition, the incidence of postweaning re-
jection (20%) has been lower (Fig. 2). 
With followups of 12 to 18 months, 62 (74%) of the 
84 Cam path-pretreated patients are on spaced weaning, 
14% are on daily monotherapy, and only 12% are re-
ceiving more than a single agent (Table 3). 
Morbidity 
In the historic controls, the incidence of symptomatic 
infections by cytomegalovirus and by BK virus was 4.5% 
and 3.2%, respectively. The incidence of posttransplant 
lymphoproliferative disease was 2%, and 9.7% had new 
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Table 3. Current Immunosuppression for Recipients with Surviving Grafts 
Historic controls 
(n = 113) 
Immunosuppression n % 
Daily monotherapy 46 41 
Multidrug therapy 67 59 
S paced dose weaning 
Once a week 
Twice a week 
Three times a week 
Every other day 
onset diabetes. These complications were not seen in the 
lymphoid depleted patients, except for a 2% incidence 
ofBK virus infection in the Thymoglobulin series and a 
2.2% incidence of new onset diabetes in the Campath 
patients. 
Pathology 
Acute rejection 
Acute cellular rejection was diagnosed and graded for 
severity according to the Banff 1997 schema of renal 
allograft pathology.24 Patients were biopsied only 
when there was a rise in creatinine. Several of these 
specimens showed intimal arteritis, glomerulitis, and 
focal or diffuse C4d deposition. The incidence of sub-
clinical rejection and its effect on graft morphology in 
the nonbiopsied patients cannot be addressed because 
no protocol biopsies were performed. It is notable 
that only one rejection episode occurred during the 
preweaning period after a Campath infusion. 
Chronic allograft nephropathy 
The numbers of recipients having a baseline biopsy within 
the first 30 days and later biopsies in the historic control, 
Thymoglobulin- and Campath-pretreated groups were 5B 
(38%), 52 (51%), and only B (9%), respectively. These 
frequencies largely reflected the relative incidence of early 
renal dysfunction from primary graft dysfunction or acute 
rejection. Although these and subsequent samples were in 
no sense protocol biopsies, enough histopathology was 
available to tentatively assess the posttransplant progression 
of CAN. 
Only a minority of the baseline (control) biopsy sam-
ples were completely free of findings that contribute to 
the 12-point maximum CAN score. The baseline CAN 
scores averaged from 1.3 to 2.0 to 2.6 in the three suc-
cessively compiled series. The acceptance of kidneys 
with an increasing incidence and severity of preexisting 
Thymoglobulln Cam path 
(n = 83) (n = 84) 
n % n % 
21 25 12 14 
6 7 10 12 
56 68 62 74 
12 
18 6 
17 40 
9 16 
donor disease reflected nationwide efforts to expand the 
organ pool, ie, by relaxing the criteria for organ 
acceptance. 
During the first year posttransplantation, CAN pro-
gressed from baseline by 2.5 points in recipients pre-
treated with Thymoglobulin, and by 3.0 points in the 
historic control patients. The I-year increase was only 
1.4 points in the recipients pretreated with Campath, 
but this was based on a very small number of biopsies. 
In years 2 and 3 posttransplantation, average CAN 
progressed an additional 1.7 and 0.34 points, respec-
tively, for the Thymoglobulin patients and 1.5 and 1.2 
points, respectively, in the historic controls. In the ab-
sence of protocol biopsies, an important caveat to the 
third year value is that very few samples were available at 
this time point: 13 in the reference group and 7 in the 
Thymoglobulin group. 
Cellular Immunologic monitoring 
Pretreatment with 5 mg/kg Thymoglobulin, as previ-
ously reported,14.25 resulted in profound depletion ofT 
cells (CD3 +) by postoperative day 1. T cell counts re-
mained below baseline for 3 months, with a gradual 
return toward baseline values. The CDB population re-
covered more promptly than the CD4 population, re-
sulting in an inverted CD4/CDB ratio that persisted up 
to 6 months posttransplant. B cells were not depleted. 
The T cell depletion was considerably greater and more 
sustained with Cam path, and in addition, B cells were 
notably depleted. 
Approximately 1 year after transplantation, more de-
tailed studies were obtained in eight of the 
Thymoglobulin-pretreated patients. Seven of the eight 
were on spaced weaning, with doses of one per week 
(n = 2), two per week (n = 1), and three per week (n = 
4). The eighth parientwas on multiple drugs. The mean 
CD4/CDB ratio, which had been 2.3 before lymphoid 
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depletion, remained less than 1.0 in five of the eight 
patients between 1.38 and 1.5 in the other three. 
At 1 year, all seven of the patients on spaced wean-
ing had donor-specific hypo reactivity demonstrated 
with MLR; the patient on multiple drugs had global 
hyporesponsiveness. In six of the seven hyporespon-
sive patients, kidney function was excellent at the 
time of testing. The kidney of the seventh patient was 
failing at the time of testing (serum creatinine 3.7 
mg/dL). Biopsy of this allograft revealed recurrent 
membranous glomerulonephritis similar to that 
which had destroyed the native kidney, but with no 
histopathologic evidence of rejection. 
In additional studies of four of the seven patients with 
MLR evidence of donor-specific hyporeactivity, the ab-
sence of donor cell killing was confirmed by cell-
mediated lymphoroxicity assay, the essential absence 
with limiting dilution assay of cytolytic T lymphocyte 
precursor, or both findings. But one of these patients, 
who was on one dose per week at the time, subsequently 
developed a mild rejection that was treated with a single 
dose of prednisone and temporary reinstitution of daily 
tacrolimus. This patient is presently on three doses of 
tacrolimus per week. 
Antibody monitoring 
Serial samples were available from 92 of the 101 
Thymoglobulin-pretreated recipients, all of whom had 
negative conventional crossmatches with their donors. 
In 59 (64%) of these patients, nonspecific anti-HLA 
antibodies were never detectable before or after trans-
plantation. In 14 of the otller 33, anticlass I antibodies 
predated transplantation (n = 12) or developed after-
ward (n = 2). These disappeared in 9 who had adequate 
subsequent samples, and they were known to persist in 
only 2 of the others. Similarly, the isolated finding of 
anticlass II antibodies before or after transplantation was 
frequently temporary or it waxed and waned. There were 
only three examples of a class switch or addition. 
Combined anticlass I and class II antibodies predated 
transplantation in five patients and developed de novo 
after 2,4, and 12 months in the three others. Of interest, 
four of the five patients with both kinds of preformed 
antibodies received zero mismatched kidneys. In two 
cases, the antibodies disappeared after transplantation. 
Except for a trend to poorer results in patients with 
anti class II antibodies (ie, graft losses or death at 8, 21, 
24, and 28 months), the preexistence or de novo devel-
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opment of the anti-HLA antibodies did not appear to be 
associated with clinical outcomes. C4D staining on bi-
opsy samples was not routinely carried out in these pa-
tients. So in these patients, a meaningful correlation of 
the serum antibody and tissue C4D complement depo-
sition was not possible. 
DISCUSSION 
The efficacy of the multiple drug protocols of immuno-
suppression in wide use for kidney transplantation has 
been judged primarily by how well these regimens pre-
vent acute rejection. The extent to which this objective 
can be accomplished was exemplified by our historic 
control group. Despite the low incidence of early rejec-
tion, however, there was a steady erosion of patient and 
graft survival that usually was related in some way to 
chronic rejection, organ-specific drug toxicity, immune 
depression per se, or combinations of these factors. 
With our revised strategy, improvement in the 
quality of recipient life replaced avoidance of acute 
rejection as the highest priority. Because the immune 
activation that can proceed to organ rejection also is 
the mandatory first step of the seminal tolerance 
mechanism of clonal exhaustion-deletion,s-7.26 the 
greater than 50% rate of early and delayed acute cel-
lular rejection in Thymoglobulin-pretreated patients 
(Fig. 2) was not necessarily viewed with alarm. Nev-
ertheless, the frequent need for urgent intensification 
of immunosuppression mandated unusually close 
physician surveillance. Despite vigilant supervision, 
there were examples of nonreversible acute rejection 
that proceeded to graft loss. These cases included, but 
were not limited to, patients who were on spaced 
weanmg. 
The obvious question raised by these observations 
concerned the risk-to-benefit ratio of the tolerogenic 
strategy overall, with particular reference to the spaced 
weaning in the Thymoglobulin series. With followups of 
2 to more than 3 years, patient survival, graft survival, 
and graft function of the Thymoglobulin-pretreated re-
cipients are equivalent overall to the results in the his-
toric controls. In the subgroup of recipients oflive donor 
kidneys, survival parameters are superior to those in the 
historic controls. Although these results are encourag-
ing, the effect of the high rate of rejection on longterm 
prognosis in the Thymoglobulin-pretreated recipients 
cannot yet be definitively evaluated. 
Protocol biopsies for histopathologic studies were not 
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systematically obtained in either the historic control or 
Thymoglobulin-pretreated patients. Instead, most of 
the biopsies were done to confirm the clinically diag-
nosed rejections that were most common in the Thymo-
globulin cohort. In cases in which multiple biopsies were 
done, the severity and progression of CAN were similar 
in the Thymoglobulin and historic control recipients. 
The lesions under both kinds of immunosuppression 
were particularly prevalent in kidneys from cadaveric 
donors. This was not surprising because it is well known 
that preexisting donor disease and ischemic injury may 
contribute to CAN27•29 and aggravate drug nephrotoxic-
ity.30 It also is well established that any degree of acute 
rejection (even of the subclinical variety) may c"ontribute 
to the arteriopathy, fibrosis, tubular atrophy, and glo-
merular loss that were the criteria for our semiquantita-
tive histopathologic scale ofCAN.30,31 
Concerns about acute rejection were largely eliminated 
after Campath was substituted for Thymoglobulin as pre-
treatment. With Campath, the incidence of rejection be-
fore spaced weaning was 1 %, and even afterward, the cu-
mulative total has been only 20%. In addition, the trend of 
better patient and graft survival relative to historic controls 
out to 1 to 2 years, are much the same as in the 
Thymoglobulin-pretreated cohort. The superior perfor-
mance of Campath may reflect, in part, the benefit of les-
sons previously accrued with the Thymoglobulin experi-
ence. For example, because of rejections associated with too 
rapid weaning in the Thymoglobulin series, spaced dosing 
beyond every other day or three times a week is no longer 
attempted until at least 1 year unless there are specific indi-
cations (eg, drug nephrotoxicity or neurotoxicity). 
It should be emphasized that it is not yet known 
whether the exceptionally complete elimination of acute 
early rejection with Campath will carry a delayed price. 
In addition to its long biologic effect (6 to 12 months), 
unbound Campath remains in the circulation for 1 to 2 
weeks after infusion (information from ILEX Inc), and 
theoretically could erode the mechanism of clonal 
exhaustion-deletion in the same way as multidrug 
posttransplant therapy.? If so, clinically silent CAN 
could develop and not be detected, particularly because 
the rate of biopsy sampling has been very low with the 
efficient avoidance of acute rejection.-
The most striking benefit of the tolerogenic immuno-
suppression in both the Thymoglobulin- and Campath-
pretreatment series was the improvement in recipient 
quality oflife. This was reflected in a very low incidence 
of infection and of de novo malignancies, and freedom 
from new onset insulin-dependent diabetes. The gains 
were clearly associated with reduced exposure to chronic 
daily immunosuppression. In both the Thymoglobulin 
and Campath series, only about 10% of the recipients 
who still bear functioning grafts are on more than a 
single immunosuppressive agent. The vast majority of 
the others are on spaced dose schedules of the mono-
therapy, including 12 patients in the Thymoglobulin 
cohort who are on one dose per week. Based on obser-
vations in adults, the Thymoglobulin-based strategy was 
adopted in April 2003 for all pediatric kidney recipients 
at our center, and more recently, Thymoglobulin was 
replaced with Campath. 
In conclusion, recipient pretreatment by lymphoid 
depletion combined with minimalistic posttransplant 
immunosuppression is an acceptable way to manage 
kidney transplant recipients. Campath currently ap-
pears to be the most effective means of pretreatment. 
But the strategy, which is designed to permit natural 
mechanisms of tolerogenesis, is neither drug nor or-
gan specific. It is most easily applied for live donor 
organ transplantation, but can be readily used for 
transplantation of cadaveric organs. Additional im-
provements should be possible, including develop-
ment of better guidelines for the optimal timing and 
extent of drug weaning. 
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